Evotec SE

EVTA

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,467.004.400.05%
CAC 407,853.56109.811.42%
DAX 4023,734.73235.411.00%
Dow JONES (US)41,249.38119.07-0.29%
FTSE 1008,585.8031.000.36%
HKSE23,549.46681.722.98%
NASDAQ17,928.920.780.00%
Nikkei 22537,644.26140.930.38%
NZX 50 Index12,676.7571.680.57%
S&P 5005,659.914.03-0.07%
S&P/ASX 2008,233.502.300.03%
SSE Composite Index3,369.2427.250.82%

Market Movers